Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Linglan Tu"'
Autor:
Yue Wu, Yawen Zhang, Xuanyu Tang, Shuhui Ye, Jingjing Shao, Linglan Tu, Junzhi Pan, Lingfeng Chen, Guang Liang, Lina Yin
Publikováno v:
Journal of Nanobiotechnology, Vol 21, Iss 1, Pp 1-18 (2023)
Abstract Background Acute lung injury (ALI) is a critical inflammatory response syndrome that rapidly develops into acute respiratory distress syndrome (ARDS). Currently, no effective therapeutic modalities are available for patients with ALI/ARDS. A
Externí odkaz:
https://doaj.org/article/9bf784c0e98141c3936ea7bf115571a8
Autor:
Zilin Li, Yiling Xi, Linglan Tu, Xu Zhang, Yue Huang, Huizong Nie, Cheng Peng, Haohuan Chai, Shenxin Zeng, Xiaoliang Zheng, Liyan Cheng
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 173, Iss , Pp 116315- (2024)
Due to resistance and BCR-ABLT315I-mutated, CML remains a clinical challenge. It needs new potential therapeutic targets to overcome CML resistance related to BCR-ABL. Our research revealed that the deubiquitinating enzyme USP28 was highly expressed
Externí odkaz:
https://doaj.org/article/5d6c517a49b24359b2b2d0c0e08ca410
Autor:
Chaoqin Guo, Nana Zhou, Yisong Lu, Mingshan Mu, Zilin Li, Xu Zhang, Linglan Tu, Jingyang Du, Xiangyu Li, Dongsheng Huang, Qiuran Xu, Xiaoliang Zheng
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 170, Iss , Pp 115955- (2024)
Immune-checkpoint blockade (ICB) therapies have been widely used in clinical treatment of cancer patients, but only 20–30% of patients benefit from immunotherapy. Therefore, it is important to decipher the molecular mechanism of resistance to ICB a
Externí odkaz:
https://doaj.org/article/0c6ad0c2d1ac41acb57e8b88b8cd754a
Autor:
Yanmei Zhang, Mengdie Fang, Shouye Li, Hao Xu, Juan Ren, Linglan Tu, Bowen Zuo, Wanxin Yao, Guang Liang
Publikováno v:
Molecular Cancer, Vol 21, Iss 1, Pp 1-17 (2022)
Abstract Background Brother of regulator of imprinted sites (BORIS) is expressed in most cancers and often associated with short survival and poor prognosis in patients. BORIS inhibits apoptosis and promotes proliferation of cancer cells. However, it
Externí odkaz:
https://doaj.org/article/37381f78e7634c4b921547c2891d3179
Autor:
Saihong Yu, Zhuduo Li, Linglan Tu, Yiyi Pu, Dongmei Yan, Xiaoju Wang, Xiaoliang Zheng, Jie Yu
Publikováno v:
Journal of Physiology and Biochemistry. 78:679-687
Conventional chemotherapy plays a key role in hepatocellular carcinoma (HCC) treatment, however, with intrinsic or acquired chemoresistance being a major constraint. Here, we aimed to identify potential target to reverse such chemoresistance. In the
SERPINE2/PN-1 regulates the DNA damage response and radioresistance by activating ATM in lung cancer
Autor:
Shirong Zhang, Qiong Wu, Yasi Xu, Linglan Tu, Lucheng Zhu, Shu-jun Xie, Shenglin Ma, Yan-yan Zhao, Jingjing Zhang, Xueqin Chen, Kan Wu, Yuhong Yang, Yuqing Wang
Publikováno v:
Cancer Letters. 524:268-283
Although the DNA damage response (DDR) is associated with the radioresistance characteristics of lung cancer cells, the specific regulators and underlying mechanisms of the DDR are unclear. Here, we identified the serine proteinase inhibitor clade E
Autor:
Ruixiang Luo, Weitao Fu, Jingjing Shao, Lin Ma, Sujuan Shuai, Ying Xu, Zheng Jiang, Zenghui Ye, Lulu Zheng, Lei Zheng, Jie Yu, Yawen Zhang, Lina Yin, Linglan Tu, Xinting Lv, Jie Li, Guang Liang, Lingfeng Chen
Publikováno v:
European Journal of Medicinal Chemistry. 253:115305
Autor:
Yiyi Pu, Dongmei Yan, Linglan Tu, Liyan Cheng, Jie Yu, Zhuduo Li, Xiaoliang Zheng, Xinbao Wang
Publikováno v:
Disease markers. 2022
Background. 5-Fluorouracil (5-FU) has been widely applied in treating cancers. However, its usage is largely limited in hepatocellular carcinoma (HCC), due to acquired resistance. Here, we aim to identify target proteins and investigate their roles i
Autor:
Xu Zhang, Linglan Tu, Haohuan Chai, Zilin Li, Yuhan Fu, Xiaoliang Zheng, Shenxin Zeng, Liyan Cheng
Publikováno v:
Journal of Oncology.
Inducing protein degradation by proteolysis-targeting chimeras (PROTACs) has gained tremendous momentum in the field for its promise in the discovery and development of new therapies. Based on our previously reported PROTAC BCR-ABL degraders, we desi
Autor:
Dongmei Yan, Linglan Tu, Haining Yuan, Liyan Cheng, Jianfei Fang, Xiaoliang Zheng, Xiaoju Wang
Publikováno v:
Scientific Reports, Vol 7, Iss 1, Pp 1-14 (2017)
Scientific Reports
Scientific Reports
Human WBSCR22 gene is involved in tumor metastasis, cell growth and invasion, however, its role in chemosensitivity to antitumor agents remains unknown. In this study, we analyzed the TCGA cohort and found the expression of WBSCR22 was significantly